NCT03126110 2025-08-14Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic MalignanciesIncyte CorporationPhase 1/2 Completed145 enrolled 47 charts
NCT02431676 2024-08-28SPIRITSidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 2 Completed121 enrolled 12 charts
NCT03665285 2024-03-08A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid TumorsNextCure, Inc.Phase 1/2 Completed109 enrolled 25 charts
NCT03241173 2022-09-27A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic MalignanciesIncyte CorporationPhase 1/2 Completed52 enrolled 25 charts
NCT02178722 2022-02-14Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected CancersIncyte CorporationPhase 1/2 Completed444 enrolled 19 charts
NCT02807844 2021-08-11Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced MalignanciesNovartisPhase 1/2 Completed141 enrolled 58 charts
NCT03277352 2021-07-22INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic MalignanciesIncyte CorporationPhase 1/2 Terminated10 enrolled 14 charts
NCT00538850 2014-03-05Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainINSYS Therapeutics IncPhase 3 Completed130 enrolled 9 charts